Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial - initial oncological outcomes

被引：0
|
作者：
Yang, X. [1 ]
Aslim, E. J. [1 ]
Ngo, N. T. [1 ]
Khor, L. Y. [1 ]
Chong, T. W. [1 ]
Yuen, J. S. P. [1 ]
Tay, K. J. [1 ]
Ho, H. S. S. [1 ]
Lee, L. S. [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
来源：
BJU INTERNATIONAL | 2019年 / 123卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
C-10162
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial
    Yang, Xinyan
    Aslim, Edwin Jonathan
    Ngo, Nye Thane
    Khor, Li Yan
    Chong, Tsung Wen
    Yuen, John Shyi Peng
    Tay, Kae Jack
    Ho, Henry Sun Sien
    Lee, Lui Shiong
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 55 - 55
  • [2] NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR) PHASE II TRIAL
    Yang, XinYan
    Aslim, Edwin Jonathan
    Nye Thane Ngo
    Khor, Li Yan
    Chong, Tsung Wen
    Yuen, John Shyi Peng
    Tay, Kae Jack
    Ho, Henry Sun Sien
    Lee, Lui Shiong
    JOURNAL OF UROLOGY, 2020, 203 : E1216 - E1217
  • [3] NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATECANCER (NEAR)-INITIAL RESULTS OF A PHASE II TRIAL
    Aslim, Edwin Jonathan
    Yang, XinYan
    Nye-Thane Ngo
    Khor, Li Yan
    Chen, Kenneth
    Chong, Tsung Wen
    Yuen, John Shyi Peng
    Tay, Kae Jack
    Ho, Henry Sun Sien
    Lee, Lui Shiong
    JOURNAL OF UROLOGY, 2019, 201 (04): : E324 - E324
  • [4] Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial - a phase II trial
    Yang, Xinyan
    Aslim, Edwin Jonathan
    Chong, Tsung Wen
    Yuen, John Shyi Peng
    Tay, Kae Jack
    Ho, Henry Sun Sien
    Lee, Lui Shiong
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 55 - 56
  • [5] Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial
    Yang, Xinyan
    Allen, John Carson
    Aslim, Edwin Jonathan
    Tay, Kae Jack
    Yuen, Shyi Peng John
    Kanesvaran, Ravindran
    Chua, Melvin Lee Kiang
    Chong, Tsung Wen
    Ho, Sun Sien Henry
    Lee, Lui Shiong
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1322 - 1330
  • [6] Initial patient-reported outcomes of neoadjuvant apalutamide (ARN509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial - a phase II trial
    Yang, X.
    Aslim, E. J.
    Chong, T. W.
    Yuen, J.
    Tay, K. J.
    Ho, H.
    Lee, L. S.
    BJU INTERNATIONAL, 2019, 123 : 38 - 38
  • [7] Editorial comments on Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial
    Kato, Manabu
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1330 - 1330
  • [8] NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
    Lui Shiong Lee
    Adelene Y. L. Sim
    Chee Wee Ong
    Xinyan Yang
    Cedric C. Y. Ng
    Wei Liu
    Vikneswari Rajasegaran
    Abner M. S. Lim
    Edwin Jonathan Aslim
    Nye-Thane Ngo
    Li-Yan Khor
    Ravindran Kanesvaran
    John Carson Jr Allen
    Kae Jack Tay
    John Shyi Peng Yuen
    Tsung Wen Chong
    Sun Sien Henry Ho
    Bin Tean Teh
    Melvin L. K. Chua
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 741 - 748
  • [9] Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
    Lui Shiong Lee
    Adelene Y. L. Sim
    Chee Wee Ong
    Xinyan Yang
    Cedric C. Y. Ng
    Wei Liu
    Vikneswari Rajasegaran
    Abner M. S. Lim
    Edwin Jonathan Aslim
    Nye-Thane Ngo
    Li-Yan Khor
    Ravindran Kanesvaran
    John Carson Jr Allen
    Kae Jack Tay
    John Shyi Peng Yuen
    Tsung Wen Chong
    Sun Sien Henry Ho
    Bin Tean Teh
    Melvin L. K. Chua
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 803 - 803
  • [10] Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.
    Giesen, Alexander
    Devos, Gaetan
    Tosco, Lorenzo
    Baldewijns, Marcella
    Gevaert, Thomas
    Goffin, Karolien
    Bidakhvidi, Niloefar Ahmadi
    Laenen, Annouschka
    Raskin, Yannic
    Van Haute, Carl
    Goeman, Lieven
    de Meerleer, Gert
    Berghen, Charlien
    Devlies, Wout
    Claessens, Frank
    Van Poppel, Hendrik
    Everaerts, Wouter
    Joniau, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345